| FDA reviews olmesartan safety record, cites CV deaths in trials - TheHeart.Org |
|
|
TheHeart.OrgThe primary end points of the two trials were dominated by measures of renal function. In the Randomized Olmesartan and Diabetes Microalbuminuria Prevention ... read more |